Goldman Sachs Adjusts Price Target on Regeneron Pharmaceuticals to $1,292 From $1,180, Maintains Buy Rating
Goldman Sachs Adjusts Price Target on Regeneron Pharmaceuticals to $1,292 From $1,180, Maintains Buy Rating
高盛将再生元制药公司的目标价从1,180美元升至1,292美元，且仍维持买入评级。
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册
资讯热榜
更新时间